Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Ryerson

Showing results (71-80 of 328) with videos related to

Pageof 33
Sort By:
Frontiers in Physiology|August 6, 2020
Cardiopulmonary Exercise Testing in Patients With Interstitial Lung DiseaseYannick Molgat-Seon, Michele R Schaeffer, Christopher J Ryerson, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|August 11, 2017
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absenceMichele R Schaeffer, Yannick Molgat-Seon, Christopher J Ryerson, et al.
Journal of Thoracic Imaging|August 10, 2019
Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease: State of the Art and Future DirectionsDaniela Castillo-Saldana, Cameron J Hague, Harvey O Coxson, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2025
Reply to Moor <i>et al.</i> and Egashira <i>et al.</i>Anna J Podolanczuk, Gary M Hunninghake, David A Schwartz, et al.
Current Opinion in Supportive and Palliative Care|May 31, 2019
Supplemental oxygen for the management of dyspnea in interstitial lung diseaseMichele R Schaeffer, Yannick Molgat-Seon, Christopher J Ryerson, et al.
American Journal of Respiratory and Critical Care Medicine|January 14, 2017
Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the AirChristopher J Ryerson, Tamera J Corte, Fernando J Martinez, et al.
Expert Opinion on Investigational Drugs|June 16, 2020
Shedding light on developmental drugs for idiopathic pulmonary fibrosisPaolo Spagnolo, Francesco Bonella, Christopher J Ryerson, et al.
BMJ Open Respiratory Research|June 24, 2025
Association of vaccination status and immunosuppression with mortality of SARS-CoV-2 infection in patients with fibrotic interstitial lung diseaseKathryn Donohoe, Kerri A Johannson, Helene Manganas, et al.
Clinics in Chest Medicine|May 13, 2019
Exercise Pathophysiology in Interstitial Lung DiseaseYannick Molgat-Seon, Michele R Schaeffer, Christopher J Ryerson, et al.
BMC Pulmonary Medicine|April 21, 2022
A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapiesAlyson W Wong, John Koo, Christopher J Ryerson, et al.
Pageof 33

Showing results (71-80 of 328) with videos related to

Sort By:
Pageof 33
Frontiers in Physiology|August 6, 2020
Cardiopulmonary Exercise Testing in Patients With Interstitial Lung DiseaseYannick Molgat-Seon, Michele R Schaeffer, Christopher J Ryerson, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|August 11, 2017
Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absenceMichele R Schaeffer, Yannick Molgat-Seon, Christopher J Ryerson, et al.
Journal of Thoracic Imaging|August 10, 2019
Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease: State of the Art and Future DirectionsDaniela Castillo-Saldana, Cameron J Hague, Harvey O Coxson, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2025
Reply to Moor <i>et al.</i> and Egashira <i>et al.</i>Anna J Podolanczuk, Gary M Hunninghake, David A Schwartz, et al.
Current Opinion in Supportive and Palliative Care|May 31, 2019
Supplemental oxygen for the management of dyspnea in interstitial lung diseaseMichele R Schaeffer, Yannick Molgat-Seon, Christopher J Ryerson, et al.
American Journal of Respiratory and Critical Care Medicine|January 14, 2017
Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the AirChristopher J Ryerson, Tamera J Corte, Fernando J Martinez, et al.
Expert Opinion on Investigational Drugs|June 16, 2020
Shedding light on developmental drugs for idiopathic pulmonary fibrosisPaolo Spagnolo, Francesco Bonella, Christopher J Ryerson, et al.
BMJ Open Respiratory Research|June 24, 2025
Association of vaccination status and immunosuppression with mortality of SARS-CoV-2 infection in patients with fibrotic interstitial lung diseaseKathryn Donohoe, Kerri A Johannson, Helene Manganas, et al.
Clinics in Chest Medicine|May 13, 2019
Exercise Pathophysiology in Interstitial Lung DiseaseYannick Molgat-Seon, Michele R Schaeffer, Christopher J Ryerson, et al.
BMC Pulmonary Medicine|April 21, 2022
A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapiesAlyson W Wong, John Koo, Christopher J Ryerson, et al.
Pageof 33